# Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis

> **NCT04892212** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Lupus Nephritis
- Immunosuppression
- Effect of Drug

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT04892212
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-30
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-10-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04892212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04892212, "Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04892212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*